Medivir AB (CHIX:MVIRS) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:MVIRS Medivir AB CHIX:MVIRS
58 GF Score
Price kr2.00
GF Value kr1.34
! 3 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB  (CHIX:MVIRs) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medivir AB Cyclically Adjusted PS Ratio Related Terms


Medivir AB Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted PS Ratio Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.95 3.12 3.52 11.71 36.19

Medivir AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.75 25.33 28.60 4.40 3.97

CHIX:MVIRS vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PS Ratio falls into.


CHIX:MVIRS
58GF Score
Medivir AB CHIX:MVIRS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medivir AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medivir AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.002/134.6100*134.6100
=0.002

Current CPI (Jun. 2026) = 134.6100.

Medivir AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.642 101.138 0.854
201612 0.247 102.022 0.326
201703 0.507 102.022 0.669
201706 0.270 102.752 0.354
201709 0.169 103.279 0.220
201712 0.139 103.793 0.180
201803 0.132 103.962 0.171
201806 0.080 104.875 0.103
201809 0.083 105.679 0.106
201812 0.377 105.912 0.479
201903 0.055 105.886 0.070
201906 0.103 106.742 0.130
201909 0.047 107.214 0.059
201912 0.039 107.766 0.049
202003 0.202 106.563 0.255
202006 0.111 107.498 0.139
202009 0.030 107.635 0.038
202012 0.042 108.296 0.052
202103 0.184 108.360 0.229
202106 0.015 108.928 0.019
202109 0.012 110.338 0.015
202112 0.204 112.486 0.244
202203 0.007 114.825 0.008
202206 0.007 118.384 0.008
202209 0.016 122.296 0.018
202212 0.034 126.365 0.036
202303 0.006 127.042 0.006
202306 0.029 129.407 0.030
202309 0.012 130.224 0.012
202312 0.060 131.912 0.061
202403 0.004 132.205 0.004
202406 0.010 132.716 0.010
202409 0.008 132.304 0.008
202412 0.009 132.987 0.009
202503 0.005 132.825 0.005
202506 0.013 133.699 0.013
202509 0.008 133.480 0.008
202512 0.024 133.380 0.024
202603 0.002 133.550 0.002
202606 0.002 134.610 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medivir AB (CHIX:MVIRS) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr2.00 is trading 49% above its estimated GF Value™ of kr1.34.

Key valuation signals for CHIX:MVIRS:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: kr1.34 vs. price of kr2.00 (49% above fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the CHIX:MVIRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
58GF Score

Get the complete analysis for CHIX:MVIRS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.00
Price
kr1.34
GF Value